-+ 0.00%
-+ 0.00%
-+ 0.00%
Ibutinib capsules, a subsidiary of Tianyu Co., Ltd. (300702.SZ), obtained a drug registration certificate
Share
Listen to the news

Zhitong Finance App News, Tianyu Co., Ltd. (300702.SZ) issued an announcement. Zhejiang Nuode Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for ibutinib capsules approved and issued by the State Drug Administration. This drug is suitable for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Fahrenheit macroglobulinemia, etc. According to statistics, the sales volume of ibutinib capsules in domestic sample hospitals and physical pharmacies in cities in 2025 is about 399 million yuan (data from the Miintranet).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending